Peter Fecci, MD PhD, is currently a Professor of Neurosurgery, Pathology, Immunology, and Biomedical Engineering at Duke University, where he also serves as the Director for the Duke Center for Brain and Spine Metastasis, as well as for the Duke Brain Tumor Immunotherapy Program. A neurosurgeon-scientist, Dr. Fecci focuses clinically on intrinsic brain tumors, both primary and metastatic. In the research realm, he heads an NIH-funded laboratory that focuses on integrating strategies for reversing cancer-induced T cell dysfunction with current immune-based platforms. For his research contributions, he was a recent recipient of the Cancer Research Institute Lloyd J. Old STAR Award and was likewise inducted into the American Society for Clinical Investigation. Dr. Fecci also serves as multi-PI for the Duke R25 training grant. His recent work on brain tumor-induced T cell sequestration and exhaustion has produced numerous high-profile publications. He is now actively engaged in exploring novel drug targets and therapeutics that his group has uncovered for side-stepping brain tumor-imposed immune dysfunction and for newly licensing immune-based approaches in this patient population.